Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer
Keywords: سرطان تخمدان مجدد; Ovarian cancer; Topotecan; 3-day schedule; Recurrent ovarian cancer